Mechanism of Bicalutamide to Breast Cancer Cell Lines MDA-MB-453 and Inhibitory Effects of Its Combination with Everolimus
10.3971/j.issn.1000-8578.2021.20.0819
- VernacularTitle:比卡鲁胺对乳腺癌细胞株MDA-MB-453的作用机制及与依维莫司联用的效果评估
- Author:
Yuqin ZHANG
1
;
Yunfei LU
;
Haitian ZHANG
Author Information
1. Department of Breast Disease, Guangxi International Zhuang Medical Hospital, Nanning 530201, China
- Publication Type:Research Article
- Keywords:
Bicalutamide;
Everolimus;
Breast cancer;
Drug combination
- From:
Cancer Research on Prevention and Treatment
2021;48(3):239-243
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of bicalutamide on migration and invasion of androgen receptor(AR) positive breast cancer cells and related mechanism, and the effect of mTOR inhibitor everolimus combined with bicalutamide on the proliferation of MDA-MB-453 cells. Methods Western blot was used to detect the expression change of mTOR, p-mTOR and p-S6 in breast cancer cell lines before and after bicalutamide treatment. Transwell assay was used to detect the cell viability. MTT assay was used to detect the proliferation of MDA-MB-453 cells treated by the combination of bicalutamide and everolimus. The combined effect of the two drugs was calculated by Jin Zhengjun's method. Results After six days of bicalutamide treatment, the expression of mTOR, p-mTOR and p-S6 were decreased in MDA-MB-453 cells (Ρ =0.034, 0.05, 0.03). The invasion and migration were inhibited in MDA-MB-453 cells (migration: t =4.88, P =0.001, invasion: t =2.684, P =0.028). The proliferation of MDA-MB-453 cells was inhibited after the treatment of bicalutamide combined with everolimus, and the Q value were all greater than 1.15. Conclusion Bicalutamide could inhibit the invasion and migration of MDA-MB-453, and the inhibition effect is affected by the expression level of AR. The combination of bicalutamide and everolimus could synergistically inhibit the proliferation of AR positive breast cancer cells.
